Catalano, A.; Adlesic, M.; Kaltenbacher, T.; Klar, R.F.U.; Albers, J.; Seidel, P.; Brandt, L.P.; Hejhal, T.; Busenhart, P.; Röhner, N.;
et al. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers 2021, 13, 1852.
https://doi.org/10.3390/cancers13081852
AMA Style
Catalano A, Adlesic M, Kaltenbacher T, Klar RFU, Albers J, Seidel P, Brandt LP, Hejhal T, Busenhart P, Röhner N,
et al. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers. 2021; 13(8):1852.
https://doi.org/10.3390/cancers13081852
Chicago/Turabian Style
Catalano, Antonella, Mojca Adlesic, Thorsten Kaltenbacher, Rhena F. U. Klar, Joachim Albers, Philipp Seidel, Laura P. Brandt, Tomas Hejhal, Philipp Busenhart, Niklas Röhner,
and et al. 2021. "Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition" Cancers 13, no. 8: 1852.
https://doi.org/10.3390/cancers13081852
APA Style
Catalano, A., Adlesic, M., Kaltenbacher, T., Klar, R. F. U., Albers, J., Seidel, P., Brandt, L. P., Hejhal, T., Busenhart, P., Röhner, N., Zodel, K., Fritsch, K., Wild, P. J., Duyster, J., Fritsch, R., Brummer, T., & Frew, I. J.
(2021). Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers, 13(8), 1852.
https://doi.org/10.3390/cancers13081852